Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Oct. 13 — Gov. Jerry Brown (D) vetoed a bill Oct. 11 that would have allowed patients in California with life-threatening illnesses to obtain investigational treatments not yet approved by the Food and Drug Administration, saying he wants to give a federal program a chance to work.
A.B. 159 by Assemblyman Ian Calderon (D), the Right To Try Act, would have made California the 25th state to give patients access to investigational drugs and medical devices. Brown pointed to the FDA's recently updated compassionate use program for drugs as the reason for his veto. He is the first U.S. governor to veto right-to-try legislation.
“The proposed changes to this program will streamline access to these drugs,” Brown said in his veto message. “Before authorizing an alternative state pathway, we should give this federal expedited process a chance to work.”
Calderon faulted Brown for giving the FDA more time.
“Time is the one thing our terminally ill don't have,” Calderon said in an Oct. 12 news release. “I wish he would have given terminally ill Californians the hope of having more time to spend with their families by allowing them expedited access to potentially life-saving drugs.”
A.B. 159 passed both houses of the Legislature with nearly unanimous support.
Kurt Altman, director of national affairs and special counsel for the Goldwater Institute, called on lawmakers to override the veto. The Arizona-based institute designed the law.
“Governor Brown has deprived Californians of the right to try to save their lives when their mortality hangs in the balance,” Altman said.
The bill would have limited access to the treatments to those who likely only have a few months to live, have considered all other FDA-approved options, and haven't been accepted into a clinical trial. It included rules for physician recommendations, informed consent, Institutional Review Board approval and review, and limitations on insurance coverage.
The measure also limited the ability of patients or their families to file civil litigation stemming from use of the investigational drugs and treatments.
The Legislature adjourned for the year Sept. 11, and reconvenes in January for the second year of its two-year session.
To contact the reporter on this story: Laura Mahoney in Sacramento, Calif., at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
More information about A.B. 159 is available at http://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201520160AB159.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)